• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib.

作者信息

Abdelrahman R A, Begna K H, Al-Kali A, Hogan W J, Litzow M R, Tefferi A

机构信息

Division of Hematology and Department of Medicine, Mayo Clinic, Rochester, MN, USA.

出版信息

Leukemia. 2015 Feb;29(2):498-500. doi: 10.1038/leu.2014.286. Epub 2014 Sep 25.

DOI:10.1038/leu.2014.286
PMID:25252872
Abstract
摘要

相似文献

1
Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib.对111例接受莫洛替尼或芦可替尼治疗的骨髓纤维化患者的缓解情况和长期停药率的修订评估。
Leukemia. 2015 Feb;29(2):498-500. doi: 10.1038/leu.2014.286. Epub 2014 Sep 25.
2
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.Momelotinib对比最佳可用疗法治疗既往接受过鲁索替尼治疗的骨髓纤维化患者（SIMPLIFY 2）：一项随机、开放标签的3期试验
Lancet Haematol. 2018 Feb;5(2):e73-e81. doi: 10.1016/S2352-3026(17)30237-5. Epub 2017 Dec 20.
3
Momelotinib versus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: an efficacy/safety analysis in the Japanese subgroup of the phase 3 randomized SIMPLIFY-1 trial.Momelotinib 对比鲁索利替尼在初治原发性骨髓纤维化患者中的疗效/安全性分析：SIMPLIFY-1 研究日本亚组的 3 期随机对照研究。
Int J Hematol. 2024 Sep;120(3):314-324. doi: 10.1007/s12185-024-03822-z. Epub 2024 Aug 7.
4
Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial.SIMPLIFY-1 试验中根据基线血红蛋白水平的骨髓纤维化患者亚组中的 Momelotinib 与 Ruxolitinib 的比较。
Leuk Lymphoma. 2024 Jul;65(7):965-977. doi: 10.1080/10428194.2024.2328800. Epub 2024 Mar 19.
5
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.107 例接受 JAK1/JAK2 抑制剂芦可替尼治疗的骨髓纤维化患者的长期结果：与匹配的历史对照相比具有生存优势。
Blood. 2012 Aug 9;120(6):1202-9. doi: 10.1182/blood-2012-02-414631. Epub 2012 Jun 20.
6
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.SIMPLIFY-1：一项在初治的骨髓纤维化患者中比较莫洛替尼与芦可替尼的III期随机试验。
J Clin Oncol. 2017 Dec 1;35(34):3844-3850. doi: 10.1200/JCO.2017.73.4418. Epub 2017 Sep 20.
7
Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies.骨髓纤维化患者从 SIMPLIFY 研究中获得有意义的症状改善。
Value Health. 2024 May;27(5):607-613. doi: 10.1016/j.jval.2024.01.014. Epub 2024 Feb 2.
8
Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis.JAK1和JAK2抑制剂莫洛替尼治疗骨髓纤维化的长期疗效和安全性
Leukemia. 2018 Apr;32(4):1035-1038. doi: 10.1038/leu.2017.330. Epub 2017 Nov 16.
9
Momelotinib for the treatment of myelofibrosis.莫雷洛替尼治疗骨髓纤维化。
Blood. 2024 Aug 15;144(7):708-713. doi: 10.1182/blood.2023023719.
10
[Momelotinib as first-line or second-line treatment following ruxolitinib in patients with primary or secondary myelofibrosis].[莫洛替尼作为芦可替尼之后原发性或继发性骨髓纤维化患者的一线或二线治疗]
Bull Cancer. 2024 Sep;111(9):796-798. doi: 10.1016/j.bulcan.2024.04.010. Epub 2024 Jun 4.

引用本文的文献

1
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis.摘要：Pelabresib 联合鲁索替尼治疗初治骨髓纤维化的效果。
J Clin Oncol. 2023 Nov 10;41(32):4993-5004. doi: 10.1200/JCO.22.01972. Epub 2023 Mar 7.
2
The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes.骨髓纤维化中 JAK 抑制剂治疗失败的临床困境：预测特征和结局。
Cancer. 2022 Jul 15;128(14):2717-2727. doi: 10.1002/cncr.34222. Epub 2022 Apr 6.
3
Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis.

本文引用的文献

1
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report.修订后的骨髓纤维化反应标准：国际工作组-骨髓增生性肿瘤研究和治疗（IWG-MRT）和欧洲白血病网络（ELN）共识报告。
Blood. 2013 Aug 22;122(8):1395-8. doi: 10.1182/blood-2013-03-488098. Epub 2013 Jul 9.
2
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis.CYT387，一种 JAK1 和 JAK2 抑制剂，在骨髓纤维化中的安全性和疗效。
Leukemia. 2013 Jun;27(6):1322-7. doi: 10.1038/leu.2013.71. Epub 2013 Mar 5.
3
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
JAK1和JAK2抑制剂莫洛替尼治疗骨髓纤维化的长期疗效和安全性
Leukemia. 2018 Apr;32(4):1035-1038. doi: 10.1038/leu.2017.330. Epub 2017 Nov 16.
4
Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms.慢性骨髓增殖性肿瘤发病机制与治疗的当代见解。
Leuk Lymphoma. 2016 Jul;57(7):1517-26. doi: 10.1080/10428194.2016.1185783. Epub 2016 May 31.
5
How can we know if new drugs are effective in myeloproliferative neoplasm-associated myelofibrosis?我们如何才能知道新药在骨髓增殖性肿瘤相关的骨髓纤维化中是否有效？
Leukemia. 2016 Jul;30(7):1453-5. doi: 10.1038/leu.2016.75. Epub 2016 Apr 29.
6
Identification of myeloproliferative neoplasm drug agents via predictive simulation modeling: assessing responsiveness with micro-environment derived cytokines.通过预测模拟模型鉴定骨髓增殖性肿瘤药物制剂：评估微环境衍生细胞因子的反应性
Oncotarget. 2016 Jun 14;7(24):35989-36001. doi: 10.18632/oncotarget.8540.
7
Myeloproliferative neoplasms and personalized medicine: the perfect match?骨髓增殖性肿瘤与个性化医疗：完美匹配？
Haematologica. 2015 Dec;100(12):1493-4. doi: 10.3324/haematol.2015.137182.
芦可替尼治疗骨髓纤维化的双盲、安慰剂对照试验。
N Engl J Med. 2012 Mar 1;366(9):799-807. doi: 10.1056/NEJMoa1110557.
4
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.芦可替尼与最佳可用疗法治疗骨髓纤维化的 JAK 抑制作用比较。
N Engl J Med. 2012 Mar 1;366(9):787-98. doi: 10.1056/NEJMoa1110556.
5
Long-term outcome of treatment with ruxolitinib in myelofibrosis.芦可替尼治疗骨髓纤维化的长期疗效
N Engl J Med. 2011 Oct 13;365(15):1455-7. doi: 10.1056/NEJMc1109555.
6
Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.选择性 JAK2 抑制剂 TG101348 治疗骨髓纤维化的安全性和疗效。
J Clin Oncol. 2011 Mar 1;29(7):789-96. doi: 10.1200/JCO.2010.32.8021. Epub 2011 Jan 10.
7
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.DIPSS plus：一种改良的原发性骨髓纤维化动态国际预后评分系统，纳入了核型、血小板计数和输血状态的预后信息。
J Clin Oncol. 2011 Feb 1;29(4):392-7. doi: 10.1200/JCO.2010.32.2446. Epub 2010 Dec 13.
8
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.INCB018424，一种 JAK1 和 JAK2 抑制剂，在骨髓纤维化中的安全性和疗效。
N Engl J Med. 2010 Sep 16;363(12):1117-27. doi: 10.1056/NEJMoa1002028.
9
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).国际工作组（IWG）关于骨髓化生伴骨髓纤维化治疗反应的共识标准，适用于骨髓纤维化研究与治疗国际工作组（IWG-MRT）。
Blood. 2006 Sep 1;108(5):1497-503. doi: 10.1182/blood-2006-03-009746. Epub 2006 May 4.